OncLive TV

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Idoroenyi Amanam, MD, discusses criteria for selecting patients with myelofibrosis who may benefit from JAK inhibitors.

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Laura J. Chambers, DO, discusses challenges patients with ovarian cancer face in accessing PARP inhibitor treatment.

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.

David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Andrea Wolf, MD, MPH, discusses challenges in conducting randomized controlled trials to assess the role of surgery in the treatment of mesothelioma.

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Shirish M. Gadgeel, MD, discusses long-term follow-up data from the MARIPOSA study for patients with EGFR-positive advanced non–small cell lung cancer.

Nagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.

Shyam A. Patel, MD, PhD, discusses the impact of donor-engrafted clonal hematopoiesis on the risk of disease relapse and survival outcomes with allo- and auto-HSCT.

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Amitkumar Mehta, MD, discusses FDA-approved treatment options for patients with diffuse large B-cell lymphoma and follicular lymphoma in later lines.

Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.